Find a Parkview Health Clinical Trial
1 results found
Current Studies
Primary Outcome Measures : Part 1: To determine the navtemadlin Phase 3 dose [ Time Frame: 12 months ] Safety review committee (SRC) will determine the navtemadlin Phase 3 dose for Part 2 based on safety data from Part 1 Part 2: To compare progression-free (PFS) survival by independent review...